Acton raises $15 million and licenses its first product
This article was originally published in Scrip
Executive Summary
Acton Pharmaceuticals has raised $15 million through a series A round of financing led by Sequoia Capital. The US company also said it had completed a licensing agreement for Aerospan (flunisolide HFA, 80µg), an inhaled corticosteroid for the treatment of asthma, from Forest Laboratories.